Targeting two receptors instead of the one targeted by fezolinetant, the new elinzanetant did not show the liver safety ...

Pathogenic activating point mutations in the LRRK2 kinase cause autosomal-dominant familial Parkinsońs disease (PD). In cultured cells, mutant LRRK2 causes a deficit in de novo cilia formation and ...

A strategy that simultaneously targets motor neurons, astrocytes, and microglia in ALS was found to extend survival in a ...

PSC-derived cells and micro-physiological systems provide significant advancements in enhancing neuronal disease models, ...

Neuroplasticity is key to brain health, facilitating learning and recovery while combating age-related cognitive decline and ...

The human brain has 100 billion neurons and nearly 1,000 trillion synaptic ... Management Institute (CMI), having qualified as a Level 3 Team leader with distinction in 2023.

The Phase 1 clinical trial is expected to enroll about 60 participants to test how safe and well tolerated multiple doses of ...

How would your experience change if you could see, in real time, how the billions of cells and neurons of your brain and body orchestrate ... then contract for 3 seconds, relax for 3 seconds, then ...

Low serum sodium concentrations in the blood are called hyponatremia, a prevalent clinical electrolyte disorder. In contrast ...

Bayer presents detailed results from OASIS 3 phase III study of elinzanetant to treat VMS associated with menopause at 2024 TMS meeting: Berlin Thursday, September 12, 2024, 11:00 ...

Researchers have discovered a mechanism behind dopamine dysregulation syndrome (DDS) in Parkinson’s patients treated with Levodopa. Their study found that Levodopa induces abnormal activation of ...